“William Ringo, Pfizer's Senior Vice President, Worldwide Business ... - Investors Business Daily” plus 3 more |
- William Ringo, Pfizer's Senior Vice President, Worldwide Business ... - Investors Business Daily
- Business News - Am770chqr.com
- Heinz fiscal 3rd-quarter profit falls - Daily Finance
- Research and Markets: Wal-Mart de Mexico - SWOT Framework Analysis - Earthtimes
| William Ringo, Pfizer's Senior Vice President, Worldwide Business ... - Investors Business Daily Posted: 25 Feb 2010 12:56 PM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. NEW YORK, Feb 25, 2010 (BUSINESS WIRE) -- Pfizer Inc. today announced that William Ringo will retire from the company. Mr. Ringo made many important contributions to advance the company's innovative business development activities. "Bill has accomplished a great deal in positioning Pfizer for future success," said Jeff Kindler, chairman and chief executive officer, Pfizer. "He has helped diversify Pfizer's portfolio through our acquisition of Wyeth; worked to create a new world-leading, specialist HIV company, called ViiV Healthcare, through our joint venture with GlaxoSmithKline; and played a leadership role in securing rights to novel, promising compounds." "He also connected the company more closely with the expanding opportunities in biotechnology," Mr. Kindler said. "I know I join all Pfizer colleagues in thanking Bill for his tireless efforts and wishing him and his family all the best as he embarks on the next stage of his life." Mr. Ringo joined Pfizer in April 2008, after retiring from Eli Lilly & Company, where over his 28-year tenure he held a number of senior positions. Between working for Lilly and Pfizer he served in leadership roles for both venture capital and biotechnology companies. "It has been a real pleasure to be part of Pfizer's Executive Leadership Team," Mr. Ringo said. "Based on my four decades of experience in the industry, I truly believe the future for Pfizer is extremely bright, as our colleagues provide quality medicines to patients around the world," he added. Mr. Ringo, whose retirement will be effective April 30, 2010, will help his successor during a transition period. Kristin Peck, who will succeed Mr. Ringo, has been named Senior Vice President of Worldwide Business Development, Strategy and Innovation. Most recently, she played a leadership role in the integration of Wyeth's global operations, while serving as Senior Vice President of Worldwide Strategy and Innovation. Working closely with the business leadership, Ms. Peck will assume responsibility for business development activities, ensuring their alignment with Pfizer's strategic objectives. She will report directly to Mr. Kindler and join Pfizer's Executive Leadership Team. "Kristin has already been playing a leadership role in strategic planning for the company. Her knowledge, expertise and energy make her an excellent choice for this leadership position," Mr. Kindler said. "Kristin will work closely with me and other Pfizer executives to advance our business development goals effectively and with an efficient use of our owners' capital." Ms. Peck joined Pfizer in 2004 in the company's strategic planning organization. Prior to Pfizer, she was a principal with the Boston Consulting Group, focusing on strategy and merger-related issues in the pharmaceutical and financial services industries, and worked in real estate financial services and private equity at Prudential and The O'Connor Group. Ms. Peck earned her bachelor's degree from Georgetown University and her M.B.A. from Columbia Business School. SOURCE: Pfizer Inc. Pfizer Inc. Copyright Business Wire 2010 See Also
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Posted: 25 Feb 2010 06:47 PM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. TOKYO - Toyota Motor Corp. is likely to miss its output target in North America by 20 per cent due to slumping sales amid massive recalls, Japan's top business daily said Friday. Toyota's production in North America is now seen at 350,000 units from February to April, down by 20 per cent from its original target, the Nikkei business daily said, citing no sources. Toyota spokeswoman Ririko Takeuchi could not confirm the report Friday, saying the company has not released production data in the region. The Nikkei said the world's biggest automaker, mired in massive global recalls, has already told auto parts suppliers about a fall in its production target. Toyota has recalled 8.5 million vehicles, more than six million of them in the United States - the automaker's biggest market. The recall crisis battered Toyota's pristine reputation for safety and quality. Toyota President Akio Toyoda on Wednesday appeared before Congress and repeatedly apologized for safety problems that have resulted in massive recalls. He visited the assembly line at the company's largest North American manufacturing plant Thursday and met with Transportation Secretary Ray LaHood, repeating pledges to boost safety efforts. To cope with falling sales following the recalls, Toyota said it was halting production temporarily in San Antonio, Texas, and Georgetown, Kentucky, in March and April. The Kentucky plant, which makes the Camry, Avalon and Venza vehicles, also plans to take a non-production day on Feb. 26. The Texas plant makes the Tundra pickup truck. Toyota's sales in the United States tumbled 16 per cent even though sales by most other rivals rebounded from last year's dismal results. If slumping sales in the United States continue, Toyota may have to suspend output in North America further and downgrade its worldwide output projection this year. Takeuchi said the company does not release global output data. But she said Toyota aims to sell 8.27 million vehicles worldwide in 2010, up 6 per cent year-on-year. Content Provided By Canadian Press. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Heinz fiscal 3rd-quarter profit falls - Daily Finance Posted: 25 Feb 2010 06:44 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. NEW YORK -Food maker H.J. Heinz Co. said rising sales in Asia's emerging markets helped its third-quarter revenue rise 13 percent, but the cost of selling frozen food businesses in the U.S. and U.K. cut into its profit, which fell 6 percent. Heinz, maker of Ore-Ida potatoes and Classico pasta sauce, as well as its namesake ketchup, benefited as consumers ate at home more often during the recession. But its U.S. sales have fallen for much of the past year, so it is marketing its products more and developing new products — such as its "Dip & Squeeze" ketchup packets due in the fall — and it is focusing on its emerging markets for growth. Its profit fell to $228.5 million, or 72 cents per share, from $242.3 million in the quarter that ended Jan. 27, or 76 cents per share, a year earlier. But it earned 83 cents per share excluding costs related to selling the two businesses. That's a penny more than the company forecast and 6 cents more than the average prediction of analysts polled by Thomson Reuters, who typically exclude such one-time items. Heinz earned 76 cents per share last year on that basis. Heinz, which makes a wide array of products, sold a frozen hors d'oeuvres business in the U.S. and a private-label frozen desserts business in the U.K. With sales rising 41 percent in Asia and 12 percent in Europe, the company's third-quarter revenue rose to $2.68 billion from $2.38 billion a year earlier. Analysts expected revenue of $2.66 billion. The sales jump in Heinz's Asia and South Pacific region was led by sales in Indonesia, China and India and offset by lower volume in Australia. The company's North American consumer product sales rose 7 percent to $815 million and its sales to U.S. food service businesses fell 3 percent to $355 million. Total U.S. volume grew 4 percent, driven by new product introductions, consumer coupons, increased advertising and co-marketing with retailers. The campaign promoted Heinz-branded products in the third quarter and is now expanding to its Weight Watchers Smart Ones, Ore-Ida, Classico and T.G.I. Fridays brands. In the U.K., volume rose 9 percent, helped by a "It has to be Heinz," marketing campaign. Heinz — which is based in Pittsburgh but derives much of its business in foreign markets — said its growth in emerging markets was driven by nutritional drinks Complan and Glucon D in India, ABC brand sauces and drinks in Indonesia and Heinz ketchup in Russia. Total volume rose 1.2 percent. CFO Art Winkleblack said volume would have risen 3 percent if not for declines in the company's U.S. Foodservice arm, which suffered from lower consumer spending at restaurants. The company is in the midst of a two-year plan to reduce its product offerings in that unit. Heinz reiterated its full-year earnings outlook of $2.82 to $2.85 per share from continuing operations. Analysts expect a profit of $2.84 per share. Shares fell 69 cents, or 1.5 percent, to $45.23 during midday trading. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Research and Markets: Wal-Mart de Mexico - SWOT Framework Analysis - Earthtimes Posted: 26 Feb 2010 06:21 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/dc1718/walmart_de_mexico) has announced the addition of the "Wal-Mart de Mexico - SWOT Framework Analysis" company profile to their offering. SWOT Analysis, is a strategic planning tool used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project or in a business venture. It involves specifying the objective of the business venture or project and identifying the internal and external factors that are favorable and unfavorable to achieving that objective. The aim of any SWOT analysis is to identify the key internal and external factors that are important to achieving the objective. SWOT analysis groups key pieces of information into two main categories: Internal factors - The strengths and weaknesses internal to the organization. External factors - The opportunities and threats presented by the external environment. The internal factors may be viewed as strengths or weaknesses depending upon their impact on the organization's objectives. What may represent strengths with respect to one objective may be weaknesses for another objective. The factors may include all of the 4P's; as well as personnel, finance, manufacturing capabilities, and so on. The external factors may include macroeconomic matters, technological change, legislation, and socio-cultural changes, as well as changes in the marketplace or competitive position. The results are often presented in the form of a matrix. Key Topics Covered: A. Executive Summary B. A Brief Profile of the Company C. SWOT Framework Analysis C.1 Strengths to Build Upon C.2 Weaknesses to Overcome C.3 Opportunities to Exploit C.4 Threats to Overcome D. Glossary of Terms For more information visit http://www.researchandmarkets.com/research/dc1718/walmart_de_mexico
Research and Markets Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Business - Bing News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |

The wave of giant biopharma mergers that hit in 2009 will continue in the years ahead, according to a new Morningstar report on M&A activity across the health care sector. Consolidation makes financial sense in some instances, says Damien Conover, a strategist and senior pharmaceutical analyst ...
The name AmerisourceBergen may not roll easily off the tongue, but chances are the products it distributes have been part of your life and well-being. The company is a major distributor of pharmaceuticals to hospitals, clinics, surgery centers, nursing homes, long-term care facilities and to ...
0 comments:
Post a Comment